Tuesday, Feb 11 2025 | Time 17:06 Hrs(IST)
image
Business EconomyPosted at: Jan 23 2025 6:20PM


Senores Pharma net up 142 pc to Rs 17.2 crore in Q3

New Delhi, Jan 23 (UNI) Senores Pharmaceuticals on Thursday reported 142 percent jump in net profit year-on-year at Rs 17.2 crore in the October-December quarter of FY25 (Q3FY25), as against Rs 7.1 crore in the same quarter of FY24.
Income from operations zoomed 35 percent year-on-year to Rs 106.4 crore in Q3FY25, from Rs 78.7 crore in Q3FY24, the company said in a regulatory filing.
Commenting on the results, Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, “We are pleased to report strong performance for Q3 and the nine-month period of FY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets.”
In Regulated Markets, robust growth in the CDMO/CMO segment was partly offset by a softer performance in the Marketed Products segment, which was impacted by the high base of Q3FY24. The consolidation of acquired businesses has resulted in strong growth in the Emerging Markets segment for Q3FY25. Year-on-year, the Regulated Markets and Emerging Markets businesses grew by approximately 100% and over 10 times, respectively, for 9MFY25, he said.
In 9MFY25, the company launched one new product and received ANDA approval for five products in the Regulated Markets business, bringing our total ANDA approvals to 24.
Our Emerging Markets business is growing well through portfolio and footprint expansion. Our registered product portfolio in the Emerging Markets business expanded to 267 products. With a strong product portfolio, we are now realigning our go-to-market models to make our Emerging Markets operations more profitable, the company said.
We are seeing significant traction and scale-up in our CDMO/CMO segment. Currently, we manufacture 21 products in this business and expect faster growth with the addition of new products, customers, and increased wallet share from existing customers.
We remain focused on executing our business strategies across segments and are confident that healthy growth will continue in the year ahead, Shah added.
UNI SKB CS1820
Please log in to get detailed story.
Tags: #Senores Pharma net up 142 pc to Rs 17.2 crore in Q3
More News

VST Tillers Tractors reports 29 pc Revenue growth in Q3

11 Feb 2025 | 2:47 PM

Chennai, Feb 11 (UNI) VST Tillers Tractors Limited (VST), India’s leading farm
equipment manufacturer, on Tuesday announced that it has registered a 29 per
cent growth in Q3 Revenue.

see more..

Titagarh Rail Systems Limited announces management rejig

11 Feb 2025 | 2:45 PM

Kolkata, Feb 11 (UNI) India’s leading Railway Systems provider Titagarh announced important management reorganization and strengthening, as well as venturing into new areas of growth.

see more..

Quality Power Electrical Equipments Limited IPO opens on Feb 14

11 Feb 2025 | 1:11 PM

Mumbai Feb 11 (UNI) The initial public offering of energy transmission equipment and power technologies firm Quality Power will open for public subscription on February 14, the company said on Tuesday.

see more..

IEW’25 set to become major event: Hardeep Puri

10 Feb 2025 | 10:06 PM

New Delhi, Feb 10 (UNI) India Energy Week 2025 is set to be the first major global event on the energy calendar that is expected to have a transformative impact on the energy market, said Minister of Petroleum & Natural Gas, Hardeep Singh Puri.

see more..

Shrijee Lifestyle to Unveil Sustainable and Festive Collections at Bharat Tex 2025

10 Feb 2025 | 3:36 PM

Shrijee Lifestyle to Unveil Sustainable and Festive Collections at Bharat Tex 2025

see more..
image